The Oxford-AstraZeneca covid vaccine.
Karwai Tang | Getty Images
LONDON — Denmark introduced Thursday it should quickly droop the use of the coronavirus vaccine developed by AstraZeneca and the University of Oxford.
The Danish Health Authority mentioned it will quickly cease utilizing the shot in its vaccination program as a precaution “after reports of severe cases of blood clots in people who have been vaccinated with the COVID-19 vaccine from AstraZeneca.”
“Against this background, the European Medicines Agency has launched an investigation into the AstraZeneca vaccine. One report relates to a death in Denmark. At present, it cannot be concluded whether there is a link between the vaccine and the blood clots,” the well being authority mentioned in a press release.
It didn’t specify what number of reports of blood clots there had been, or the place that they had originated.
The announcement comes after the same transfer in Austria at first of the week, the place authorities are investigating the loss of life of one individual and the sickness of one other after they acquired doses of the vaccine.
Shares of AstraZeneca on the London market slipped 2.4% on Thursday morning. The University of Oxford wouldn’t touch upon the announcement when contacted by CNBC.
A spokesperson for AstraZeneca mentioned the corporate was conscious of the assertion made by the Danish Health Authority that it is at the moment investigating potential antagonistic results associated to the vaccine.
“Patient safety is the highest priority for AstraZeneca. Regulators have clear and stringent efficacy and safety standards for the approval of any new medicine, and that includes COVID-19 Vaccine AstraZeneca. The safety of the vaccine has been extensively studied in Phase III clinical trials and Peer-reviewed data confirms the vaccine is generally well tolerated,” AstraZeneca mentioned in a press release to CNBC.
Søren Brostrøm, director of the National Board of Health in Denmark, insisted that the 14-day suspension was a precaution whereas investigations came about.
“It is important to emphasize that we have not opted out of the AstraZeneca vaccine, but that we are putting it on hold. There is good evidence that the vaccine is both safe and effective. But both we and the Danish Medicines Agency have to react to reports of possible serious side effects, both from Denmark and other European countries,” he mentioned.
Austrian well being authorities suspended the use of batch ABV5300 of the AstraZeneca vaccine after an individual was identified with a number of thrombosis (formation of blood clots inside blood vessels) and died 10 days after vaccination, and one other was hospitalized with pulmonary embolism after being vaccinated.
“The latter is now recovering,” the European Medicines Agency mentioned Wednesday.
However, the EMA added that “there is currently no indication that vaccination has caused these conditions, which are not listed as side effects with this vaccine.”
The EMA famous that the identical batch ABV5300 was delivered to 17 EU international locations and includes 1 million doses of the vaccine.
“Some EU countries have also subsequently suspended this batch as a precautionary measure, while a full investigation is ongoing. Although a quality defect is considered unlikely at this stage, the batch quality is being investigated,” the EMA mentioned.
It added that its security committee was reviewing the problem and “investigating the cases reported with the batch as well as all other cases of thromboembolic events, and other conditions related to blood clots, reported post-vaccination.”
“The information available so far indicates that the number of thromboembolic events in vaccinated people is no higher than that seen in the general population.”
As of March 9, “22 cases of thromboembolic events had been reported among the 3 million people vaccinated with COVID-19 Vaccine AstraZeneca in the European Economic Area,” the EMA mentioned.
Late-stage medical trials discovered the AstraZeneca-Oxford shot to have a mean efficacy of 70% in defending towards the virus. A newer examine by Oxford researchers discovered that the Covid vaccine was 76% efficient at stopping symptomatic an infection for 3 months after a single dose, and that the efficacy fee truly rose with an extended interval between the primary and second doses.
The AstraZeneca-Oxford vaccine is being relied upon closely within the U.Ok. and European Union’s immunization rollouts.